Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rallybio (RLYB) EBITDA (2023 - 2026)

Rallybio's EBITDA history spans 3 years, with the latest figure at -$5.9 million for Q4 2025.

  • On a quarterly basis, EBITDA rose 47.44% to -$5.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$9.0 million, a 84.36% increase, with the full-year FY2025 number at -$9.0 million, up 84.36% from a year prior.
  • EBITDA hit -$5.9 million in Q4 2025 for Rallybio, down from $16.0 million in the prior quarter.
  • Over the last five years, EBITDA for RLYB hit a ceiling of $16.0 million in Q3 2025 and a floor of -$20.0 million in Q4 2023.
  • Historically, EBITDA has averaged -$11.8 million across 3 years, with a median of -$13.7 million in 2024.
  • Biggest five-year swings in EBITDA: fell 11.36% in 2024 and later surged 242.73% in 2025.
  • Tracing RLYB's EBITDA over 3 years: stood at -$20.0 million in 2023, then soared by 44.33% to -$11.1 million in 2024, then surged by 47.44% to -$5.9 million in 2025.
  • Business Quant data shows EBITDA for RLYB at -$5.9 million in Q4 2025, $16.0 million in Q3 2025, and -$9.7 million in Q2 2025.